Santen Pharmaceutical (OTCMKTS:SNPHY) Hits New 1-Year High – Should You Buy?

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) shares hit a new 52-week high on Tuesday . The stock traded as high as $13.9250 and last traded at $13.90, with a volume of 4301 shares changing hands. The stock had previously closed at $13.4850.

Wall Street Analyst Weigh In

Separately, Zacks Research upgraded shares of Santen Pharmaceutical to a “hold” rating in a research report on Monday, April 13th. One equities research analyst has rated the stock with a Hold rating, Based on data from MarketBeat, Santen Pharmaceutical presently has an average rating of “Hold”.

Santen Pharmaceutical Price Performance

The company has a market capitalization of $4.30 billion and a PE ratio of 0.10. The company has a 50 day moving average of $11.99 and a two-hundred day moving average of $11.32.

About Santen Pharmaceutical

Santen Pharmaceutical Co, Ltd. is a Japan‐based specialty pharmaceutical company focused exclusively on ophthalmology. Headquartered in Osaka, Santen engages in the research, development, manufacture and marketing of prescription and over‐the‐counter products for the diagnosis and treatment of eye diseases. Its core product portfolio includes therapies for glaucoma, dry eye, retinal disorders, uveitis and post‐operative care, as well as surgical equipment and diagnostic agents designed to support comprehensive eye care.

With roots tracing back to the late 19th century, Santen has grown from a domestic manufacturer to a global ophthalmic specialist.